Compile Data Set for Download or QSAR
maximum 50k data
Found 9 Enz. Inhib. hit(s) with all data for entry = 2242
TargetP2Y purinoceptor 13(Homo sapiens (Human))
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM359085(US10220040, Compound Ih-(S-isomer))
Affinity DataEC50:  3.37E+7nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2Y purinoceptor 13(Homo sapiens (Human))
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM359083(US10220040, Compound Va)
Affinity DataEC50:  5.52E+7nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2Y purinoceptor 13(Homo sapiens (Human))
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM359084(US10220040, Compound Ih-(R-isomer))
Affinity DataEC50:  4.24E+7nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2Y purinoceptor 13(Homo sapiens (Human))
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM359086(US10220040, Compound IIa)
Affinity DataEC50:  4.03E+7nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2Y purinoceptor 13(Homo sapiens (Human))
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM50118225(ARL 69931MX | Adenosine triphosphate derivative | ...)
Affinity DataEC50:  6.32E+3nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetP2Y purinoceptor 13(Homo sapiens (Human))
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM359088(US10220040, Compound IIc)
Affinity DataEC50:  6.63E+6nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2Y purinoceptor 13(Homo sapiens (Human))
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM359089(US10220040, Compound VIIa)
Affinity DataEC50:  4.03E+7nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2Y purinoceptor 13(Homo sapiens (Human))
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM359090(US10220040, Compound XIa)
Affinity DataEC50:  4.89E+4nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetP2Y purinoceptor 13(Homo sapiens (Human))
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM359087(US10220040, Compound IIb)
Affinity DataEC50:  2.99E+5nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent